Live Investor Briefing Prescient Therapeutics

Prescient Therapeutics (ASX: PTX)

Live Investor Briefing

Register for an Upcoming Webcast

Please join Prescient CEO and managing director Steven Yatomi-Clarke for an investor briefing.

In this session, Steven will discuss:

  • Their broad portfolio of well advanced assets developed with world-leading partners including Yale, UPenn, Oxford, Moffitt & Peter MacCallum.
  • Their two first-in-class targeted therapies PTX-100 and PTX-200, currently in clinical development and showing encouraging activity.
  • Their two next generation cell therapy platform technologies – OmniCAR and CellPryme – and how they overcome the limitations of existing and emerging cell therapies.

This is a live and interactive online session, and participants are encouraged to ask questions. Spots are limited, so secure yours today.

Can’t make this time, register to receive the replay.

Book Your Spot

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.


Steven Yatomi-Clarke (Speak feature)

Steven Yatomi-Clarke

CEO and Managing Director

Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development. He has been a collaborator on various immunotherapy research projects.